Skip to main content
. 2022 Jan 4;8(1):20552173211065731. doi: 10.1177/20552173211065731

Figure 1.

Figure 1.

Flow chart of infectious risk assessment

* to evaluate new infections acquired during DMT or the reactivation of latent infection. The evaluation was performed after six months for injective DMTs and after twelve months for oral DMTs.

** serial assessment based on the infectious risk and first-level of infectious risk assessment after six months.